Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer

Cancer Research

Volumn 67, Issue 5, 2007, Pages 2160-2168

  Nathan, Cherie Ann O ^a,b   Amirghahari, Nazanin ^a   Rong, Xiaohua ^a   Giordano, Tony ^a   Sibley, Don ^a   Nordberg, Mary ^a   Glass, Jonathan ^a   Agarwal, Anshul ^a   Caldito, Gloria ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; INITIATION FACTOR 4E BINDING PROTEIN 1; LUCIFERASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMSIROLIMUS; VASCULOTROPIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FLUORESCENCE IN SITU HYBRIDIZATION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PLOIDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DRUG EVALUATION, PRECLINICAL; GENE DOSAGE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; NEOPLASM, RESIDUAL; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PTEN PHOSPHOHYDROLASE; SIROLIMUS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33947235680     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2449     Document Type: Article

References (50)

1. Jemal ACL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
2. Nathan CA, Franklin S, Abreo FW, Nassar R, De Benedetti A, Glass J. Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol 1999; 17:2909-14.
3. Nathan CA, Amirghahari N, Abreo F, et al. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2004;10:5820-7.
4. De Benedetti A, Harris AL. eIF4E expression in tumors: its possible role in progression of malignancies. Int J Biochem Cell Biol 1999;31:59-72.
5. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996;15:658-64.
6. Shamji AF, Nghiem P, Schreiber SL. Integration of growth factor and nutrient signaling: implications for cancer biology. Mol Cell 2003;12:271-80.
7. 1-arresting rapamycin-receptor complex. Nature 1994;369:756-8.
8. Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKB12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994;78:35-43.
9. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 2002;3: 295-304.
10. Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 1999;59:886-94.
11. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-37.
12. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
13. + ALL). Blood 2005; 106:458-63.
14. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-23.
15. Diekmann F, Gutierrez-Dalman A, Torregrosa Jose V, Oppenheimer F, Campistol Joseph M. Sirolimus monotherapy: feasible immunosuppression for long-term follow-up of kidney transplantation - a pilot experience. Transplantation 2005;80:1344-8.
16. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-9.
17. Paez J, Sellers WH. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 2003;115:145-67.
18. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63.
19. Sun T, Nordberg ML, Cotelingam JD, Veillon DM, Ryder J. Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma. Am J Hematol 2003;74:78-84.
20. Noh WC, Mondesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004;10:1013-23.
21. Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001;7:1758-64.
22. Clayman GL, el-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995;55:1-6.
23. Contag CH, Spilman SD, Contag PR, et al. Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem Photobiol 1997;66:523-31.
24. Hait WN. Updated methods for reporting clinical trials. Clin Cancer Res 2005;11:6753.
25. Lee J, Soria JC, Hassan K, et al. Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg 2001;127:1441-5.
26. Pedrero JM, Carracedo DG, Pinto CM, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005;114:242-8.
27. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000;19:6680-6.
28. Amornphimoltham P, Patel V, Sodhi A, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 2005;65:9953-61.
29. Brunn GJ, Hudson CC, Sekulic A, et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science 1997;277:99-101.
30. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 1998;12:502-13.
31. Hara K, Yonezawa K, Kozlowski MT, et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 1997;272:26457-63.
32. Montanaro L, Pandolfi PP. Initiation of mRNA translation in oncogenesis: the role of eIF4E. Cell Cycle 2004;3:1387-9.
33. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E-from translation to transformation. Oncogene 2004;23:3172-9.
34. Rhoads RE. Protein synthesis, cell growth, and oncogenesis. Curr Opin Cell Biol 1991;3:1019-24.
35. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-7.
36. Crew JP, Fuggle S, Bicknell R, Cranston DW, de Benedetti A, Harris AL. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br J Cancer 2000; 82:161-6.
37. Nathan CA, Franklin S, Abreo FW, et al. Expression of eIF4E during head and neck tumorigenesis: possible role in angiogenesis. Laryngoscope 1999;109:1253-8.
38. Scott PA, Smith K, Poulsom R, De Benedetti A, Bicknell R, Harris AL. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer 1998;77:2120-8.
39. DeFatta RJ, Nathan CA, De Benedetti A. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope 2000;110:928-33.
40. Nathan CA, Carter P, Liu L, et al. Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinoma. Oncogene 1997;15:1087-94.
41. Cuba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
42. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 2003;12:889-901.
43. Rehemtulla A, Stegman LD, Cardozo SJ, et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia 2000;2:491-5.
44. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003;101:640-8.
45. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
46. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly IV infusion of CCI-779, a novel mTOR inhibitor, in patient with cancer. J Clin Oncol 2004;22:2336-47.
47. Charpentier B, Groth CG, Backman L, et al. Bicetre hospital experience with Sirolimus-based therapy in human renal transplantation: the Sirolimus European Renal Transplant Study. Transplant Proc 2003;35:58-61S.
48. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-304.
49. Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005;14:313-28.
50. Hudes G, Carducci M, Tomczak P, et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-α (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. 2006 ASCO Annual Meeting Proceedings. Part I. J Clinical Oncol 2006; 24(18S; June 20 Supplement):LBA4.